

OCT 5 1998

K971549

G.N.P. Holdings LTD
37 Shvedia St., Danya,
Haifa-Israel

VMT™ System -Ataxiagraph
510(k) Premarket Notification
Dated: April 3, 1997

12. 510(k) Summary

THE VMT™ SYSTEM FOR THE EVALUATION OF VISUO-MOTOR PERFORMANCE

Contact: Target Health, Inc.
310 Madison Avenue, 22nd Floor
New York, NY 10017

Tel: 212 681 2100
Fax: 212 682 0151

Sponsor: Taly Hocherman
G.N.P. Holdings LTD
37 Shvedia Street, Danya,
Haifa-Israel

Tel: ++972-4-8262293/4
Fax: ++972-4-8242088

12.1 Device Name

The VMT™ System is provided as follows:

- a. Trade Name - VMT™ System
- b. Common and Descriptive Name - Ataxiagraph

12.2 Predicate Devices/ Company Names and Addresses

The predicate devices are listed below with their 510(K) clearance numbers.

The Equitest System - (K851744) NuroCom International, Inc. 9570 SE Lawnfield Road, Clackamas, Oregon 97015-96 USA

The Pro & Smart Balance Master Systems - (K946229) NeuroCom International, Inc. 9570 SE Lawnfield Road, Clackamas, Oregon 97015-96 USA

12.3 Clinical Experience

Clinical studies have been performed and have concluded that the device was safe and effective for its intended use.



OCT 5 1998

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Jules T. Mitchel, M.D.
President
Target Health, Inc.
310 Madison Avenue
22nd Floor
New York, New York 10017

Re: K971549/S004
Trade Name: VMT System
Regulatory Class: Unclassified
Product Code: LXV
Dated: July 23, 1998
Received: July 24, 1998

Dear Dr. Mitchel:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your pre-market notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Dr. Jules T. Mitchel

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,


f Celia M. Witten, Ph.D., M.D.
Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure


G.N.P. Holdings LTD
37 Shvedia St., Danya,
Haifa-Israel

VMT™ System -Ataxiagraph
510(k) Premarket Notification
Dated: April 3, 1997

8. *Indication for use*

The VMT™ System is designed for the evaluation of visuo-motor performance disturbances.

X
Prescription Use _____
(Per 21 CFR 801.109)



(Division Sign-Off)
Division of General Restorative Devices
510(k) Number K971549